Gene therapy readout helps Ultragenyx rebound

By Stephen Hansen, Associate Editor | Jan 10, 2020 | 7:14 PM GMT

Editor's note: Updated on Jan 10, 2020 at 9:11 PM GMT

Orphan disease company Ultragenyx added nearly $600 million in market cap Friday after reporting better-than-expected data for gene therapy DTX301 -- a welcome lift after clinical disappointments had weighed on the stock in 2H19.